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Adipose Tissue Collagen VI in Obesity
Magdalena Pasarica, Barbara Gowronska-Kozak, David Burk, Isabel Remedios,
David Hymel, Jeff Gimble, Eric Ravussin, George A. Bray, and Steven R. Smith
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808
Objectives: Basic science studies show that the extracellular matrix of adipose tissue, mainly rep-
resented by collagen VI, is dysfunctional in obesity and contributes to the development of the
metabolic syndrome. We hypothesized in humans that increased collagen VI 3-subunit (COL6A3)
mRNA is associated with adipose tissue macrophage chemotaxis and inflammation and that weight
gain is accompanied by changes in the expression of COL6A3.
Research Design and Methods: Adipose tissue biopsies were obtained from a cross-sectional study
(n  109), an overfeeding study (n  9), and a pioglitazone treatment study (n  14). Adipose tissue
gene expression was measured by quantitative RT-PCR, immunohistochemistry, and adipocyte
sizing by fixation with osmium and Coulter counting. Body composition was measured by dual-
energy x-ray absorptiometry and visceral adipose tissue by computed tomography. Patients with
high or low COL6A3 mRNA were compared by one-way ANOVA.
Results: In humans, immunohistochemistry revealed that COL6 is present in adipose tissue extra-
cellular matrix. COL6A3 mRNA is correlated with body mass index (r  0.60, P  0.0001) and fat mass
(r  0.41, P  0.0001). COL6A3 expression was similar in obese vs. type 2 diabetes patients. Obese
subjects with high COL6A3 mRNA had greater visceral adipose tissue mass (P  0.05), lower size of
small and medium adipocytes (P  0.05), more CD68 and CD163/MAC2 macrophages, and
increased macrophage inflammatory protein-1 and macrophage chemoattractant protein-1
mRNA (P  0.05). Eight weeks of overfeeding increased body weight and COL6A3 mRNA (P  0.05).
Pioglitazone decreased COL6A3 mRNA, and the change was inversely proportional to baseline
COL6A3 mRNA (r  0.95, P  0.0001).
Conclusion: These results are consistent with basic science data, suggesting that COL6A3 might
contribute to adipose tissue inflammation. (J Clin Endocrinol Metab 94: 5155–5162, 2009)
Adipose tissue has been extensively studied for its rolein the etiology of the metabolic syndrome. The main
focus has been on the location, quantity, and molecules
secreted from adipose tissue (1). Several basic science mod-
els support the view that the extracellular matrix in adipose
tissue is dysfunctional in obesity and contributes to the met-
abolic syndrome(2).Adiposetissueextracellularmatrixcon-
tains multiple types of collagen including I, IV, V, VI, VII,
VIII, and IX; among these collagen VI is highly enriched
in adipose tissue (3). Collagen VI 3-subunit (COL6A3)
mRNA is increased in diabetic mice (2). Obese ob/ob mice
lacking the COL6A3 gene (COL6KO) have a better meta-
bolic profile compared with wild-type mice. They also gain
less weight when fed a high-fat diet (2). COL6KO mice are
also insulin sensitive, despite larger sc adipocytes (2), which
are typically associated with decreased insulin sensitivity (4).
This suggests that COL6A3 restricts the storage of lip-
ids in sc tissue. COL6KO mice also have lower macro-
phage content in adipose tissue and decreased expression of
inflammatory molecules including the macrophage chemo-
kine, macrophage chemoattractant protein (MCP)-1, and
macrophage inflammatory protein (MIP)-1 (2).
Collagen VI (COL6) might act directly through mole-
cules that increase (lumican) or decrease (decorin) mac-
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rophage accumulation as shown by decreased lumican
and increased decorin expression in adipose tissue of
COL6KO mice (2). In human adipose tissue, we found
that adipose tissue oxygenation and COL6A3 mRNA
were significantly correlated (R 0.81, P  0.05), show-
ing that patients with greater expression of COL6A3 have
reduced adipose tissue oxygenation (5). In addition, re-
duced oxygenation was associated with adipose tissue in-
flammation (5–7). Taken together, this suggests that ad-
ipose tissue fibrosis might prevent angiogenesis and lie
upstream of reduced oxygenation and inflammation in
obese human adipose tissue.
Our aim was to explore the expression of COL6A3
in human adipose tissue. We hypothesized that in hu-
mans increased COL6A3expression is associated with
adipose tissue macrophage chemotaxis and inflamma-
tion and weight gain is accompanied by changes in
COL6A3 mRNA.
Subjects and Methods
Population and study design
There are three distinct populations investigated in this work:
a cross-sectional study, an overfeeding study, and a pioglitazone
treatment study. For all studies, subjects were
excluded if they had significant renal, cardiac,
liver, lung, or neurological disease, although
controlled hypertension was acceptable if
blood pressure was less than 140/90 mm Hg
on medications. Subjects were excluded for al-
cohol or other drug abuse or smoking and
were unwilling to abstain from caffeine and
alcohol for 48 h before biopsy. Protocols were
approved by the Institutional Review Boards
of the Pennington Biomedical Research Cen-
ter or the University of Maryland. All volun-
teers gave written informed consent after be-
ing informed of the nature of all procedures to
be performed. The study population was a
convenience sample in which we assayed ex-
isting biopsy material from our archives. As
such, we assayed essentially all of the available
samples without attempting to have an equal
number of males and females.
Cross-sectional study
Baseline data were analyzed from patients
participating in clinical studies for weight loss,
diabetes treatment, metabolic/physiological
studies, or gastric bypass surgery performed at
Pennington Biomedical Research Center or
the University of Maryland.
Overfeeding study
Six healthy young men and three women
aged 18–28 yr with a body mass index (BMI)
of 25.7  0.99 kg/m2 were admitted to the
inpatient unit and consumed a weight-maintaining diet. Energy
requirements were determined by whole room calorimetry and
weight stability over 2 wk. Subjects then consumed a diet con-
sisting of 44% fat, 15% protein, and 41% carbohydrate for 4 wk
at 40% of energy requirements. Weight gain averaged 7.7 
2.13%.
Pioglitazone treatment study
Patients with type 2 diabetes were enrolled in a study to de-
termine the effect of pioglitazone on adipose tissue (8). Diabetes
was defined by a fasting plasma glucose of 126 mg/dl or greater
at entry or fasting plasma glucose greater than 115 mg/dl and a
2-h glucose tolerance test of glucose 200 mg/dl or greater or
current use of metformin or sulfonylureas. The treatment was
given as a single daily dose of 30 mg/d each morning. The dose
of pioglitazone was increased at 45 mg/d at wk 8 if fasting plasma
glucose was greater than 100 mg/dl or the hemoglobin A1C was
greater than 7.7%. Fourteen men and women changed their
body weight on average by 1.3  2.3 kg.
Body composition
Body fat mass was measured on a dual energy X-ray absorp-
tiometer in the fan beam mode (QDR 4500; Hologic, Inc.,
Waltham, MA). Coefficient of variation for the measurement of
percentage of body fat is 1.7%. Visceral fat and abdominal sc
fat mass were measured by computer tomography (CT) scan-
ning using a GE high-speed CT scanner. From the eight cross-
sectional areas, visceral adipose tissue volume (liters) was cal-
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FIG. 1. COL6A3 is higher in obesity. Abdominal sc adipose tissue frozen tissue (A) and
paraffin-embedded sections (B) labeled for capillaries (red) and COL6 (blue). Pearson
correlation between COL6A3 mRNA and BMI (C) and COL6A3 mRNA and total fat mass in
abdominal sc adipose tissue (D) of lean (crosses), overweight, and obese patients with low
(squares), medium (stars), or high COL6A3 mRNA (filled squares).
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culated and converted to kilograms visceral adipose tissue mass
using the conversion factor 0.9193 kg/liter adipose tissue, as
previously described (9).
Laboratory measures
The following assays were done on blood drawn after at least
10 h of fasting (overnight). Glucose was analyzed using a Beck-
man-Coulter Synchron CX7 (Brea, CA) and insulin via immu-
noassay on the DPC 2000 (Diagnostic Product Corp., Los An-
geles, CA). The coefficient of variation for these assays is less
than 2.0%. The homeostasis model assessment-insulin resistant
index was calculated by multiplying the glucose (millimoles) by
the insulin (microunits per milliliter) and dividing the product by
22.5 (10).
Adipose tissue biopsy
The biopsies were obtained after at least 10 h of fasting (over-
night). Biopsy material was obtained from the following: 1) the
abdominal sc adipose tissue only (Figs. 1–4); 2) paired samples
from visceral and sc abdominal adipose tissue (supplemental Fig.
1SA, published as supplemental data on The Endocrine Society’s
Journals Online web site at http://jcem.endojournals.org); and
3) paired samples from abdominal and gluteal sc adipose tissue
(supplemental Fig. S1B). For the abdominal and gluteal sc adi-
pose tissue biopsy, the skin was anesthetized with a mixture of
lidocaine (2%) and bupivocaine (0.025%). Adipose tissue was
obtained using a Bergstrom needle and processed at the bedside
by washing in 37 C PBS. Visceral adipose tissue biopsy was
obtained under anesthesia during a gastric bypass procedure
(University of Maryland). Tissue was snap frozen for gene ex-
pression, preserved in 10% formalin for paraffin blocking or
fixed in osmium solution for adipocyte sizing.
Quantitative real-time PCR
Human total RNA from about 100 mg AT was extracted in
Trizol and purified by column purification (QIAGEN, Valencia,
CA). All primers and probes were designed using Primer Express
version 2.1 (Applied Biosystems, Foster City, CA). Sequences of
primers and probes are shown in supplemental Table S1, pub-
lished as supplemental data on The Endocrine Society’s Journals
Online web site at http://jcem.endojournals.org. Quantitative
real-time RT-PCR (11) were performed as one-step reactions in
an ABI PRISM 7900 (Applied, Biosystems) using the following
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FIG. 2. COL6A3 expression and adipose tissue distribution. A, Pearson correlation between COL6A3 mRNA and abdominal visceral adipose tissue
mass of lean (crosses), overweight and obese patients with low (squares), medium (stars), or high COL6A3 mRNA (filled squares). Both genders are
included in this analysis. Visceral adipose tissue mass (B) and adipocyte size (C) were measured in the low (white bars), medium (gray bars), and
high COL6A3 mRNA tertiles (black bars) and reported as mean  SD.
Low Med High
COL6A3 mRNA tertile
CD68 staining of subcutaneous adipose tissue
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FIG. 3. COL6A3 expression and adipose tissue inflammation. A, Abdominal sc adipose tissue was stained for CD68 macrophages.
CD163/MAC2 mRNA (B) and MIP1 and MCP1 mRNA (C) were measured in the low (white bars), medium (gray bars), and high COL6A3 mRNA
tertiles (black bars) and reported as mean  SD.
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followed by 40 cycles at 95 C for 15 sec and 60 C for 1 min. The
relative standard curve method was used to calculate the quan-
tity of the target gene for each tissue extract with an internal
control. The housekeeping gene cyclophilin B was previously
demonstrated to be stable across lean and obese subjects (5,
12–14). Therefore, each sample value was divided by the quan-
tity of cyclophilin B.
Immunomorphological analysis of adipose tissues
Frozen sc adipose tissue was incubated in blocking buffer (2
h), followed by rabbit polyclonal COL6 antibody 1:50 dilution
(catalog no. ab6588; Abcam, Cambridge, MA) overnight. Next,
sections were incubated with AlexaFlour 680 goat antirabbit
antibody (catalog no. A21076; Invitrogen, Carlsbad, CA) and
lectin-tetramethylrhodamine isothiocyanate conjugated from 10
g/ml Ulex europaeus (catalog no. L4889; Sigma-Aldrich, St.
Louis, MO) for 2 h. Images were collected using a 510 META
confocal microscope (Zeiss, New York, NY) equipped with a
20 (0.8 NA) objective and appropriate excitation lasers and
bandpass filters.
Human abdominal sc adipose tissue was fixed in Bouin’s so-
lution, dehydrated, paraffin embedded, and serially sectioned (5
m thicknesses). Sections were processed for immunohisto-
chemical detection of the COL6 and CD68. The negative control
was obtained by omitting the primary antibody during the im-
munostaining procedure. Adipose tissue sections were prepared
for staining by being deparaffinized and dehydrated with Xylene
for 20 min and incubation with 100, 90, 80, 70, and 60% eth-
anol. Slides were rehydrated with PBS (20 min).
COL6 staining
The slides were heated at 60 C for 30 min. Antigen retrieval
was performed in 1 mM EDTA (pH 8.0) for 20 min. Bond Max
stainer (Leica Microsystems, Bannockburn, IL) was used for im-
munohistochemistry. Incubation in blocking buffer was per-
formed for 1 h followed by rabbit polyclonal COL6 antibody
1:50 dilution (catalog no. ab6588; Abcam) incubation for 1 h
and rinsed with PBS four times for 10 min. AlexaFlour 680 goat
antirabbit antibody (catalog no. A21076; Invitrogen) was ap-
plied for 1 h and rinsed five times and mounted using Aqua-
Mount medium (catalog no. M7644–1; Cardinal Health, Elk
Grove, CA).
CD68 staining
Sections were treated with 3% H2O2 in methanol for 30 min
to block endogenous peroxidases followed by normal horse se-
rum to reduce nonspecific staining. Consecutive sec-
tions were incubated overnight (4 C) with the mono-
clonal primary antibody antihuman CD68 (1:100;
Santa Cruz Biotechnologies, Santa Cruz, CA). An-
tibody binding was detected with tyramide signal
amplification kit (PerkinElmer Las Inc., Waltham,
MA). Peroxidase activity was revealed using 3,3-
diaminobenzidine as a substrate. Quantitative anal-
yses were performed according to the methods out-
lined elsewhere (15). Quantitative analyses of
immunopositive cells were made with the assistance
of the Metamorph/Metavue software (Molecular
Devices, Dovington, PA). For macrophage quanti-
zation, adipocytes and macrophages were counted
from five fields and the macrophages expressed as
a percentage of total adipocytes counted. CD-68-
positive cell number was assessed based on staining intensity
in all samples by two independent observers.
Images of the stained sections were taken with a Zeiss Axio-
plan 2 upright microscope (Carl Zeiss) equipped with a Photo-
metrics CoolSnap HQ CCD camera and a plan Apochromat
20/0.75 objective lens.
Adipocyte size and number
Adipose tissue was fixed in osmium tetroxide and counted
with a Coulter counter as previously described (16, 17). Adipo-
cyte number in the abdominal sc adipose tissue was determined
by dividing the sc abdominal fat mass (multislice CT) by the
abdominal sc adipocyte mean size (18).
Statistical methods
After confirming the normal distribution using a Shapiro-
Wilk test, COL6A3 mRNA was correlated with BMI, body fat
mass, and visceral fat mass using the Pearson correlation co-
efficient. Within-subject comparison before vs. after interven-
tion and between depots was done using a paired t test. Com-
parison between the obese without diabetes and obese with
diabetes and between baseline and after weight gain was per-
formed using an unpaired t test. Comparison between low,
medium, and high COL6A3 expression tertiles was performed
using a one-way ANOVA, followed by comparisons between
the low and high COL6A3 expression tertiles using a post hoc
contrast comparison with P set as significant if less than 0.05.
Values are presented as mean  SD, unless otherwise noted.
Results
COL6A3 mRNA increases with BMI
Clinical characteristics of the patients are presented in
Table 1. Subjects were men (n  84) and women (n  25),
aged 18–54 yr, with a broad range of BMI (19.7–42.9
kg/m2), weight (52.8–128.7 kg), and body fat (7.2–57.0
kg). Abdominal sc adipose tissue mass ranged from 5.7 to
21.9 kg and abdominal visceral adipose tissue mass ranged
from 1.2 to 11.6 kg. We showed for the first time that
COL6 is present in humans in adipose tissue extracellular
matrix by immunohistochemistry (Fig. 1, A and B).
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FIG. 4. COL6A3 expression changes with overfeeding and PPAR agonist
treatment. A, COL6A3 mRNA increased after weight gain by overfeeding. B, Obese
patients with type 2 diabetes treated with a PPAR agonist decrease COL6A3 mRNA
proportional to COL6A3 baseline expression.
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positively correlated with BMI (R  0.60, P  0.0001; Fig.
1C) and total body fat mass (R  0.41, P  0.0001; Fig.
1D). Independent of BMI, sex was a significant contrib-
utor to COL6A3 mRNA expression (P  0.001) with
women having lower COL6A3 expression compared with
men (least square mean and SD: 0.63  0.1 vs. 0.95  0.1,
respectively).
Not only adipose tissue mass but also adipose tissue
distribution influences the development of the meta-
bolic syndrome. COL6A3 mRNA was strongly corre-
lated with abdominal visceral adipose tissue mass (R 
0.57, P  0.0001; Fig. 2A) but not with sc abdominal
adipose tissue mass (R  0.19, P NS). In addition,
COL6A3 mRNA expression was lower in sc compared
with visceral adipose tissue in men and women together
(2.6  1.7 vs. 10.8  12.8 AU, respectively, Mean  SD,
P  0.05; supplemental Fig. 1A), in men only (1.6  0.1
vs. 4.0  0.9 AU, respectively, P  0.05) or in women
only (3.0  1.9 vs. 13.3  14.4 AU, respectively, P 
0.05). Within the sc adipose tissue, we found that
COL6A3 mRNA was lower in abdominal vs. gluteal
adipose tissue in men and women (1.5  1.1 vs. 2.4 
1.5 AU, respectively, P  0.05, supplemental Fig. S1B),
in women only (1.6  1.6 vs. 2.5  1.8 AU, respectively,
P  0.05) but not in men only (1.5  0.6 vs. 2.4  1.4
AU, respectively, P  0.06).
Preclinical data showed that COL6KO mice are in-
sulin sensitive (2). However, in BMI-matched obese pa-
tients without or with type 2 diabetes (BMI: 34.7  3.0
vs. 35.7  4.7 kg/m2, respectively, P  NS) COL6A3
mRNA was similar (1.22  0.5 vs. 1.27  0.9 AU,
respectively, P  NS).
Obese with high COL6A3mRNA have increased
visceral adipose tissue mass and adipose tissue
inflammation independent of BMI
We observed that at BMIs higher than 28 kg/m2,
COL6A3 mRNA varied greatly (Fig. 1A). Therefore, we
split the subjects into two groups: lean (BMI  28 kg/m2)
and overweight/obese (BMI  28 kg/m2). COL6A3
mRNA was correlated with BMI in the lean group (R 
0.46, P  0.001) but not the overweight/obese group (P 
NS). The overweight/obese were split into tertiles of
COL6A3 mRNA (clinical characteristics are presented in
Table 2), which had similar BMI and similar body fat mass
TABLE 1. Clinical characteristics of the lean,






Sex (female/male) (25/18) (0/66) (8/7)
BMI (kg/m2) 25.6  2.1 33.5  3.6 35.7  4.7
Weight (kg) 74.1  9.5 104.4  12.0 101.7  19.6
Total body fat (kg) 21.4  6.9 32.6  8.3 38.0  10.1
VAT (kg) 2.6  1.4 6.3  2.0 25.6  8.7
SAT (kg) 7.3  2.0 10.2  4.4 39.8  13.2
COL6A3 mRNA
(AU)
0.37  0.22 1.20  0.50 1.27  0.95
Total body fat was measured by dual-energy x-ray absorptiometry.
Abdominal visceral adipose tissue mass (VAT) and abdominal sc adipose
tissue mass (SAT) were measured by multislice CT. COL6A3 mRNA was
measured by RT-PCR and normalized to the housekeeping gene.
TABLE 2. Clinical characteristics of overweight/obese subjects split by COL6A3 mRNA tertiles
Low COL6A3 Medium COL6A3 High COL6A3 ANOVA Post hoc high vs. low
COL6A3 mRNA (AU) 0.68  0.13 1.16  0.10 1.77  0.36 a a
Sex (female/male) (0/22) (0/22) (0/22)
Age (yr) 39  10 44  7 43  8
BMI (kg/m2) 33.4  4.0 32.9  3.6 34.1  3.1
Weight (kg) 106  12 100  13 107  10
Total body fat (kg) 15.2  7.0 16.5  3.9 17.0  5.8
VAT (kg) 5.6  2.0 6.0  1.5 7.3  2.1 a a
SAT (kg) 10.2  5.2 10.5  3.7 9.9  4.2
Mean adipocyte size (l) 0.76  0.19 0.75  0.13 0.77  0.14
Small adipocyte size (l) 0.024  0.004 0.022  0.006 0.020  0.006 a
Medium adipocyte size (l) 0.21  0.10 0.18  0.12 0.14  0.11 a
Large adipocyte size (l) 0.44  0.08 0.41  0.11 0.39  0.19
Very large adipocyte size (l) 1.43  0.52 1.36  0.40 1.60  0.47
Adipocyte number  109 13.9  6.1 13.9  4.4 13.2  5.7
Fasting glucose (mg/dl) 95  9 97  11 98  7
HOMA-IR 4.0  2.1 3.4  1.5 3.4  1.5
COL6A3 mRNA was measured by RT-PCR and normalized to the housekeeping gene. Total body fat was measured by dual-energy x-ray
absorptiometry. Abdominal visceral adipose tissue mass (VAT) and abdominal sc adipose tissue mass (SAT) were measured by multislice CT.
Subcutaneous abdominal adipose tissue samples were fixed, digested, and analyzed on a Coulter counter. The diameter of each osmium-fixed TG
droplet was used to calculate cell volume. For each participant, four subdistributions were determined: small, medium, large, and very large
adipocyte. Adipocyte number was determined by dividing the sc abdominal fat mass by the abdominal sc mean size. HOMA-IR, Homeostatic
model of assessment-insulin resistance index.
a P  0.05.
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(ANOVA, P  NS) but different body fat partitioning.
Subjects in the high COL6A3 mRNA tertile had signifi-
cantly more visceral adipose tissue (ANOVA, P  0.05;
post hoc contrast low vs. high, P  0.05; Fig. 2B). The
mean adipocyte size was not different between the low,
medium, and high COL6A3 mRNA tertiles (0.76  0.19
vs. 0.75  0.13 vs. 0.77  0.14 l, respectively, ANOVA,
P  NS; post hoc contrast low vs. high P  NS). sc adi-
pocyte number was also similar (13.9  6.1  109 vs.
13.9  4.4  109 vs. 13.2  5.7  109, respectively,
ANOVA, P  NS). However, the average size of the small
and medium adipocyte fractions was smaller in the high
COL6A3 expression tertile compared with the low
COL6A3 expression tertile subjects (ANOVA, P  NS,
post hoc contrast low vs. high P  0.05, Fig. 2C) with
similar size of the large and very large adipocytes.
CD68 and CD163/MAC2 are robust macrophage
markers. Subjects in the high COL6A3 tertile had in-
creased macrophage content in adipose tissue as shown by
higher CD68-positive macrophages per number of adipo-
cytes (0.35  0.21 vs. 0.28  0.16 vs. 0.21  0.12, re-
spectively, ANOVA, P  0.05; post hoc contrast low vs.
high P  0.05, Fig. 3A). Similarly, CD163/MAC2 mRNA
expression was higher (36.1  17.9 vs. 34.17  13.2 vs.
26.2  8.1 AU respectively, ANOVA, P  0.05; post hoc
contrast low vs. high P  0.05; Fig. 3B). This is consistent
with the increased expression of MCP1 and MIP1 ob-
served in the high COL6A3 tertile subjects (ANOVA, P 
0.05; post hoc contrast low vs. high P  0.05, Fig. 3C):
MCP1 (11.6  9.4 vs. 9.9  4.3 vs. 6.9  3.5 AU, re-
spectively) and MIP1 (6.7  4.7 vs. 5.9  3.8 vs. 3.3 
1.7 AU, respectively).
COL6A3mRNA increases with overfeeding but not
peroxisomal proliferator-activated receptor
(PPAR)- agonist treatment
Given that COL6A3 mRNA correlates with adipose
tissue inflammation, interventions that change adipose tis-
sue inflammation might act through COL6A3. Obesity is
associated with increased adipose tissue inflammation
(19). Nine patients that participated in an overfeeding
study gained weight (from 77.7  13.0 kg average at base-
line to 83.7  14.6 kg; P  0.001) and increased COL6A3
mRNA in adipose tissue from 0.4  0.4 AU at baseline to
1.1  1.1 AU (P  0.05, Fig. 4A). COL6A3 mRNA in-
crease after weight gain was bigger in subjects with low
COL6A3 expression at baseline (R  0.33, P  NS).
PPAR agonist agents remodel adipose tissue and cause
weight gain (8) along with decreasing adipose tissue in-
flammation (19, 20). Obese patients with type 2 diabetes
treated with pioglitazone, a PPAR agonist, gained weight
(from 94.6  21.1 kg at baseline to 95.9  21.0 kg) but on
average did not decrease COL6A3 mRNA (from 0.86 
0.76 at baseline to 0.57  0.26 AU; P  NS). There was
a greater fall in COL6A3 mRNA in those patients with
high COL6A3 mRNA at baseline (R  0.95, P 
0.0001; Fig. 4B). When the subject with the highest
COL6A3 mRNA change was removed, the correlation
remained significant (R  0.76, P  0.01).
Discussion
COL6A3 mRNA is increased in murine obesity. Based on
compelling data from the COL6KO mouse, Scherer and
colleagues (2) proposed that COL6 acts to constrain adi-
pocyte expansion, leading to inflammation and insulin
resistance. We found that COL6A3expression is increased
in human obesity independent of diabetes. Obesity with
high expression of COL6A3 have increased adipose tissue
inflammation and visceral adipose tissue mass. Overfeed-
ing, which increases inflammation, leads to an increase in
COL6A3 expression. PPAR agonist treatment, which de-
creases inflammation, decreases COL6A3 expression in
proportion with the baseline COL6A3. Together with the
basic science data, our results suggest that there are at least
three consequences of increased COL6 in human obesity:
first, to restrict the storage of lipid in sc adipose tissue,
leading to storage in visceral adipose tissue; second, to
reduce oxygenation of adipose tissue, which leads to in-
flammation; and third, to directly increase adipose tissue
inflammation.
We studied the expression of COL6A3 mRNA in the sc
adipose tissue of a large group of lean, overweight, and
obese men and women. COL6 is present in human adipose
tissue extracellular matrix, as shown by immunohisto-
chemistry. COL6A3 mRNA was significantly increased at
greater BMIs and greater fat mass. Because COL6A3 is a
major component of adipose tissue extracellular matrix
(3), this suggests that adipose tissue fibrosis is present in
human obesity. Interestingly, we found that women have
lower COL6A3 mRNA compared with men independent
of BMI, possibly contributing to a better metabolic profile
in women (21).
COL6 KO mice have higher insulin sensitivity com-
pared with the ob/ob (2). We found no difference in
COL6A3 expression between obese and obese with type 2
diabetes, suggesting that COL6A3 does not contribute to
the development of diabetes. This is perhaps because both
obese groups have reduced adipose tissue insulin sensitiv-
ity, but only the obese patients with type 2 diabetes had
-cell failure, which might not relate to COL6A3.
Most importantly, only the obese subjects had a large
variation in COL6A3 mRNA measured in sc adipose tis-
sue; lean subjects always had low COL6A3 mRNA. In-
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creased visceral adipose tissue mass is associated with
greater circulating inflammatory molecules, therefore
greater risk for diabetes and cardiovascular disease. Inter-
estingly, despite similar BMI and body fat, patients with
high COL6A3 mRNA had significantly more visceral ad-
ipose tissue. In addition, in the cross-sectional study, we
found that greater COL6A3 expression in sc adipose tissue
is associated with greater abdominal visceral adipose tis-
sue mass, suggesting that greater COL6A3 contributes to
the metabolic disease risk. Consistent with the COL6KO
mice (2), the average size of small and medium adipocytes
was larger in the low COL6A3 mRNA tertile subjects.
Increased abdominal vs. gluteal and visceral vs. sc dis-
tribution of adipose tissue is a risk factor for cardiovas-
cular disease and diabetes (21). We found that COL6A3
mRNA expression is lower in sc compared with visceral
and in abdominal vs. gluteal adipose tissue. The signifi-
cance is unclear but of general interest.
In parallel with the increase in COL6A3, adipose tissue
macrophage content is increased, probably due to expres-
sion of the potent proinflammatory cytokines MCP1 and
MIP1. This suggests that high COL6A3 contributes to
increased obese adipose tissue inflammation, perhaps
through reduced oxygenation of adipose tissue, which in-
duces inflammation in vitro (6, 7) and is associated with
inflammation in vivo (5).
Given that higher COL6A3 mRNA is accompanied by
adipose tissue inflammation, we hypothesized that inter-
ventions changing adipose tissue inflammation might act
through COL6A3. Increased body weight is associated
with adipose tissue inflammation (19), and we showed
that it also increases COL6A3 expression. PPAR agonist
agents cause weight gain (8) but decrease adipose tissue
inflammation and increases insulin sensitivity (19, 20).
One mechanism by which PPAR agonist treatment im-
proves adipose tissue function may be to increase vascu-
larization of adipose tissue (22). Animal studies suggest
that remodeling angiogenesis leads to a decrease in fibrosis
(23). Therefore, decreasing adipose tissue fibrosis might
lay upstream increased vascularization, increased oxygen-
ation, and decreased inflammation of adipose tissue. Al-
ternately, PPAR ligands might directly suppress the ex-
pression of COL6A3. Supporting these hypotheses, we
showed in a pilot study that obese type 2 diabetes patients
with high COL6A3 decreased COL6A3 mRNA when
treated with PPAR agonist.
In conclusion, COL6A3 expression is increased in hu-
man obesity independent of diabetes. Obese subjects with
high COL6A3 have increased adipose tissue inflammation
and increased visceral adipose tissue mass. Overfeeding
increases COL6A3 expression, whereas PPAR agonist
treatment decreases COL6A3 expression; this change is
proportional to the baseline expression of COL6A3. To-
gether these data are consistent with a model in which
fibrosis leads to local hypoxia, inflammation, and in-
creased visceral adipose tissue. Alternately, hypoxia could
increase the expression of COL6 and chemokine secretion,
leading to macrophage infiltration and inflammation. Fu-
ture studies are needed to study the direct effects of in-
creased COL6A3 expression on inflammation and the dis-
tribution of adipose tissue.
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